Long-Term Therapy of Acromegaly with SMS 201–995 (Sandostatin®)
SMS 201–995 (Sandostatin®), a long-acting analogue of somatostatin, has been shown to be effective in lowering growth hormone (GH) levels in patients with acromegaly [1, 2]. Suppression of GH levels persists for 6 to 8 h and a treatment schedule of two or three daily injections is required to maintain optimum suppression. In the present study, 2 patients who had been unsuccessfully treated by surgery or surgery and pituitary irradiation were treated with Sandostatin for 12 to 18 months and clinical and laboratory parameters were followed to determine the efficacy of treatment.
KeywordsGrowth Hormone Prolactin Level Growth Hormone Level Proton Beam Irradiation Pituitary Irradiation
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Ch’ng JLC, Sandler LM, Kraenzlin ME, Burrin JM, Joplin GF, Bloom SR (1985) Chronic treatment of acromegaly with a long-acting somatostatin analogue. Br Med J 290: 284–285CrossRefGoogle Scholar
Lamberts SWJ, Oosterman R, Neufeld M, Del Pozo E (1985) The somatostatin analogue SMS 201-995 induced long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab 60: 1161–1165CrossRefPubMedGoogle Scholar
Richmond W, Seviour PW, Teal TK, Elkeles RS (1987) Analgesic effect of somatostatin analogue (octreotide) in headache associated with pituitary tumours. Br Med J 295: 247–248CrossRefGoogle Scholar
Sandler LM, Burrin JM, Williams G, Joplin GF, Can DH, Bloom SR (1987) Effective long-term treatment of acromegaly with a long-acting somatostatin analogue (SMS 201995). Clin Endocrinol 26: 85–95CrossRefGoogle Scholar
© Springer-Verlag, Berlin Heidelberg 1988